Showing 321-330 of 3511 results for "".
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- Study: JAK Inhibitor–Excimer Laser Combination Improves Repigmentation in Pediatric Vitiligohttps://practicaldermatology.com/news/jak-inhibitorexcimer-laser-combination-improves-repigmentation-in-pediatric-vitiligo-trial/2487301/Children with progressive vitiligo treated with an oral Janus kinase (JAK) inhibitor combined with 308-nm excimer laser therapy experienced significantly greater repigmentation than those treated with topical tacrolimus and excimer laser therapy, according to
- Systematic Review Highlights Comparative Outcomes Across Molluscum Contagiosum Therapieshttps://practicaldermatology.com/news/systematic-review-highlights-comparative-outcomes-across-molluscum-contagiosum-therapies/2487169/A new systematic review evaluating treatments for molluscum contagiosum (MC) found that curettage, potassium hydroxide (KOH), autoinoculation, and podophyllotoxin demonstrated some of the highest lesion clearance rates among currently available therapies, while ne
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- Aging Cohort Analysis IDs Predictors of Stronger Epidermal Barrier Functionhttps://practicaldermatology.com/news/aging-cohort-analysis-ids-predictors-of-stronger-epidermal-barrier-function/2486981/A large population-based analysis from the Baltimore Longitudinal Study of Aging identified several demographic factors associated with stronger skin barrier function, according to findings presented by Katrina Abuabara, MD, MSCE, and colleagues.
- Reduced AMP Expression Seen in Sensitive Skin Syndrome: Pilot Studyhttps://practicaldermatology.com/news/reduced-amp-expression-seen-in-sensitive-skin-syndrome-pilot-study/2486974/A pilot study published in the Journal of the American Academy of Dermatology evaluated whether key pathophysiologic features of rosacea—Demodex colonization and antimicrobial peptide (AMP) dysregulation—are also present in
- Dr. Lisa Swanson Presents on Communication, Therapeutics, and Confidence in Treating Children at Noahhttps://practicaldermatology.com/news/dr-lisa-swanson-presents-on-communication-therapeutics-and-confidence-in-treating-children-at-noah/2486876/At the 67th Noah Worcester Dermatological Society Annual Meeting, Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, delivered the Alfred L. Weiner Lecture titled “Afraid to Treat Kids? Here are some Pearls to Help!” The session focused on practical, clinic-ready stra
- CKD Linked to Higher Complication Risk After Mohs Surgeryhttps://practicaldermatology.com/news/ckd-linked-to-higher-complication-risk-after-mohs-surgery/2486676/Chronic kidney disease (CKD) was associated with increased postoperative complications following Mohs micrographic surgery (MMS), according to results of a study published as a Research Letter in the Journal of Drugs in Dermatology Authors evaluated
- Meta-Analysis: Similar AK Clearance With PDT and Cryotherapyhttps://practicaldermatology.com/news/meta-analysis-finds-similar-ak-clearance-with-pdt-and-cryotherapy/2486675/A recent systematic review and meta-analysis suggested comparable efficacy and safety of photodynamic therapy (PDT) and cryotherapy for lesion clearence in actinic keratosis (AK). The analysis, published in the Journal of
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th